Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone

Silva, Rummenigge Oliveira; Costa, Bruna Lopes da; Silva, Flávia Rodrigues da; Silva, Carolina Nunes da; Paiva, Mayara Brandão de; Dourado, Lays Fernanda Nunes; Malachias, A.; Araújo, Adriano Antunes de Souza; Nunes, Paula Santos; Silva-Cunha, Armando

doi:10.1016/j.ijpharm.2019.118466

Cited by 20 publications

(10 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found one report of corneal wound healing where liquid crystal nanoparticles were used. The nanoformulation decreased the injured corneal area by ~50% and reduced inflammation after 82 h of administration compared to non-encapsulated drug (Silva et al, 2019).…”

Section: Resultsmentioning

confidence: 94%

The Therapeutic Benefits of Nanoencapsulation in Drug Delivery to the Anterior Segment of the Eye: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Background: Although numerous nanoparticle formulations have been developed for ocular administration, concerns are being raised about a possible mismatch between potential promises made by the field of nanoparticle research and demonstration of actual therapeutic benefit. Therefore, the primary focus of this present review was to critically assess to what extent nanoencapsulation of ocular drugs improved the therapeutic outcome when treating conditions in the anterior segment of the eye.Methods: A systematic search was conducted using Medline, PubMed, and Embase databases as well as Google Scholar for published peer-reviewed articles in English focusing on conventional nanoparticles used as drug delivery systems to the anterior segment of the eye in in vivo studies. The major therapeutic outcomes were intraocular pressure, tear secretion, number of polymorphonuclear leucocytes and pupil size. The outcome after encapsulation was compared to the non-encapsulated drug.Results: From the search, 250 results were retrieved. Thirty-eight studies met the inclusion criteria. Rabbits were used as study subjects in all but one study, and the number of animals ranged from 3 to 10. Coated and uncoated liposomes, lipid-based and polymeric nanoparticles, as well as micelles, were studied, varying in both particle size and surface charge, and encapsulating a total of 24 different drugs, including 6 salts. The majority of the in vivo studies demonstrated some improvement after nanoencapsulation, but the duration of the benefit varied from less than 1 h to more than 20 h. The most common in vitro methods performed in the studies were drug release, transcorneal permeation, and mucin interaction.Discussion: Nanoparticles that are small and mucoadhesive, often due to positive surface charge, appeared beneficial. Although in vitro assays can unravel more of the hidden and sophisticated interplay between the encapsulated drug and the nanoparticle structure, they suffered from a lack of in vitro—in vivo correlation. Therefore, more research should be focused towards developing predictive in vitro models, allowing rational design and systematic optimization of ocular nanoparticles with minimal animal experimentation.

show abstract

Section: Resultsmentioning

confidence: 94%

The Therapeutic Benefits of Nanoencapsulation in Drug Delivery to the Anterior Segment of the Eye: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, in a subsequent study of corneal alkali burns in dogs, the beneficial effect of suberanilohydroxamic acid on corneal fibrosis was not confirmed [63]. Pirfenidone was also shown to enhance corneal wound healing not only by exerting antifibrotic effects but also by shortening the re-epithelialization time and exerting antiangiogenic effects [57,58,62].…”

Section: Antifibrotic Strategiesmentioning

confidence: 96%

“…Galectin-3 inhibitor [59] Ophthalmic (eye drops) EMP2 antibody blockade [60] Subconjunctival injection Humanized antibody H1L1 [61] Subconjunctival injection Antifibrotic strategies Suberanilohydroxamic acid [63] Topical Pirfenidone [57,58,62] Topical/eye drops/contact lens Re-epithelialization Gelatin/ascorbic acid cryogels [53] Surgical insertion tFNAs [55] Topical…”

Section: Antiangiogenic Strategiesmentioning

confidence: 99%

Recent Advances in Experimental Burn Models

Hao

Nourbakhsh

2021

Biology

View full text Add to dashboard Cite

Experimental burn models are essential tools for simulating human burn injuries and exploring the consequences of burns or new treatment strategies. Unlike clinical studies, experimental models allow a direct comparison of different aspects of burns under controlled conditions and thereby provide relevant information on the molecular mechanisms of tissue damage and wound healing, as well as potential therapeutic targets. While most comparative burn studies are performed in animal models, a few human or humanized models have been successfully employed to study local events at the injury site. However, the consensus between animal and human studies regarding the cellular and molecular nature of systemic inflammatory response syndrome (SIRS), scarring, and neovascularization is limited. The many interspecies differences prohibit the outcomes of animal model studies from being fully translated into the human system. Thus, the development of more targeted, individualized treatments for burn injuries remains a major challenge in this field. This review focuses on the latest progress in experimental burn models achieved since 2016, and summarizes the outcomes regarding potential methodological improvements, assessments of molecular responses to injury, and therapeutic advances.

show abstract

“…The anti-inflammatory efficacy test for topical ophthalmic formulations consists in administering a proinflammatory substance to animals, i.e., carrageenan [188] or arachidonic acid, and a more specific induced inflammation model exists, such as autoimmune uveitis [216] or ethanol burn [162].…”

Section: Efficacy Testingmentioning

confidence: 99%

Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation

et al. 2020

View full text Add to dashboard Cite

Ocular inflammation is one of the most common symptom of eye disorders and diseases. The therapeutic management of this inflammation must be rapid and effective in order to avoid deleterious effects for the eye and the vision. Steroidal (SAID) and non-steroidal (NSAID) anti-inflammatory drugs and immunosuppressive agents have been shown to be effective in treating inflammation of the ocular surface of the eye by topical administration. However, it is well established that the anatomical and physiological ocular barriers are limiting factors for drug penetration. In addition, such drugs are generally characterized by a very low aqueous solubility, resulting in low bioavailability as only 1% to 5% of the applied drug permeates the cornea. The present review gives an updated insight on the conventional formulations used in the treatment of ocular inflammation, i.e., ointments, eye drops, solutions, suspensions, gels, and emulsions, based on the commercial products available on the US, European, and French markets. Additionally, sophisticated formulations and innovative ocular drug delivery systems will be discussed. Promising results are presented with micro- and nanoparticulated systems, or combined strategies with polymers and colloidal systems, which offer a synergy in bioavailability and sustained release. Finally, different tools allowing the physical characterization of all these delivery systems, as well as in vitro, ex vivo, and in vivo evaluations, will be considered with regards to the safety, the tolerance, and the efficiency of the drug products.

show abstract

Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone

Cited by 20 publications

References 67 publications

The Therapeutic Benefits of Nanoencapsulation in Drug Delivery to the Anterior Segment of the Eye: A Systematic Review

The Therapeutic Benefits of Nanoencapsulation in Drug Delivery to the Anterior Segment of the Eye: A Systematic Review

Recent Advances in Experimental Burn Models

Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation

Contact Info

Product

Resources

About